Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Delcath Systems is a specialty pharmaceutical and medical device company focused on oncology, specifically developing and commercializing its proprietary Percutaneous Hepatic Perfusion (PHP) system for delivering high-dose chemotherapy directly to the liver to treat primary and metastatic liver cancers. The company's lead product, HEPZATO KIT (melphalan/Hepatic Delivery System), received FDA approval in August 2023 for metastatic uveal melanoma, a rare and deadly cancer with limited treatment options. With minimal revenue base and high cash burn, the stock trades on commercial launch execution, reimbursement dynamics, and potential label expansion opportunities.
Delcath generates revenue by selling single-use HEPZATO KIT systems to hospitals and cancer centers performing PHP procedures. Each kit contains the proprietary catheter system and melphalan chemotherapy drug for one treatment session. Pricing power derives from orphan drug exclusivity (7 years from August 2023 approval), lack of direct competitors for hepatic-directed therapy in uveal melanoma, and the severity of the disease (median survival without treatment under 12 months). The company must establish reimbursement codes, train interventional radiologists and oncologists on the procedure, and build a specialized sales force. Gross margins are high (83%+) due to the specialized nature and limited competition, but operating leverage remains negative due to commercialization infrastructure costs exceeding the nascent revenue base.
Quarterly procedure volume updates and HEPZATO KIT unit sales - the primary commercial traction metric
Reimbursement milestones including CMS coverage decisions, J-code assignments, and private payer policies
Clinical data releases from ongoing studies or real-world evidence supporting efficacy and safety
Cash runway updates and financing announcements given negative operating cash flow
Regulatory developments including potential label expansions to other liver cancer indications (hepatocellular carcinoma, colorectal liver metastases)
Partnership or licensing deals for international markets (EU, Asia-Pacific)
Reimbursement uncertainty - CMS and private payers may establish inadequate reimbursement rates or restrictive coverage policies that limit commercial viability despite FDA approval
Limited patient population - Metastatic uveal melanoma affects approximately 400-500 newly diagnosed US patients annually, creating a small addressable market that may not support standalone profitability without label expansion
Procedural adoption barriers - PHP requires specialized interventional radiology skills and infrastructure not available at all cancer centers, limiting geographic penetration
Regulatory risk for label expansion - Future growth depends on clinical trial success and FDA approval for additional liver cancer indications with significantly larger patient populations
Systemic therapy advances - Checkpoint inhibitors (Opdivo, Keytruda) and targeted therapies continue evolving for uveal melanoma, potentially offering less invasive alternatives that could limit PHP adoption
Alternative locoregional therapies - Radioembolization (Y90), chemoembolization (TACE), and ablation techniques compete for liver-directed treatment market share
Biosimilar and generic competition post-exclusivity - After orphan drug exclusivity expires in August 2030, generic melphalan formulations could enter if competitors develop alternative delivery systems
Cash burn and dilution risk - With negative operating cash flow of approximately $13M annually and current ratio of 15.06 suggesting adequate near-term liquidity, the company will likely require additional capital raises within 12-24 months, creating dilution risk for existing shareholders
Revenue concentration risk - Single-product company with no diversification; commercial failure of HEPZATO would eliminate the investment thesis
Manufacturing and supply chain risk - Reliance on third-party manufacturers for specialized catheter components and melphalan drug substance creates potential supply disruption vulnerabilities
low - Healthcare spending, particularly for life-threatening cancers with limited alternatives, demonstrates minimal correlation to GDP cycles. Uveal melanoma patients and oncologists make treatment decisions based on clinical need rather than economic conditions. However, hospital capital budgets for new procedural technologies can face pressure during recessions, potentially slowing adoption rates at new centers.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for pre-profitable biotech/medtech companies with cash flows years in the future, and (2) Increased financing costs for future capital raises needed to fund operations until profitability. The company's minimal debt (0.01 D/E) limits direct interest expense impact, but equity dilution risk increases when raising capital in higher-rate environments. Conversely, falling rates support valuation expansion and cheaper financing access.
Minimal direct credit exposure. The company does not extend significant credit to customers (hospital payments typically processed through established procurement systems). However, tightening credit conditions could indirectly impact hospital capital expenditure budgets and willingness to adopt new procedural technologies requiring upfront investment in training and infrastructure.
growth - The stock attracts speculative growth investors and biotech specialists willing to accept binary risk/reward profiles. With 1,701% revenue growth (off minimal base), negative profitability, and early commercialization stage, the investment thesis centers on successful commercial execution and potential label expansion creating multi-year revenue growth runway. The -42.6% one-year return and high volatility reflect typical pre-profitable specialty pharma trading dynamics. Not suitable for value or income investors given negative cash flows and no dividend. Momentum traders may engage around clinical/regulatory catalysts.
high - Small-cap ($300M market cap) pre-profitable medical device companies exhibit elevated volatility driven by binary catalysts (reimbursement decisions, clinical data, financing events), low trading liquidity, and sensitivity to broader biotech sector sentiment. The stock likely trades with beta >1.5 relative to broader markets and even higher beta to biotech indices (XBI, IBB). Single-day moves of 10-20% around material news events are typical for this profile.
